Effectiveness of Phenolic Antioxidants in Experimental Model of Benign Prostatic Hyperplasia
- Autores: Borovskaya T.1, Kamalova S.1, Grigor’eva V.1, Poluektova M.1, Vychuzhanina A.1, Kuchin A.2, Chukicheva I.2, Buravlev E.2, Fomina T.1, Plotnikov M.1, Goldberg V.3, Dygai A.1
-
Afiliações:
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
- Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
- Research Institute of Oncology, Tomsk National Research Medical Center
- Edição: Volume 167, Nº 5 (2019)
- Páginas: 606-609
- Seção: General Pathology and Pathological Physiology
- URL: https://journals.rcsi.science/0007-4888/article/view/241957
- DOI: https://doi.org/10.1007/s10517-019-04580-3
- ID: 241957
Citar
Resumo
Experimental model of sulpiride-provoked benign prostatic hyperplasia was employed to comparatively assess the effect of phenolic antioxidants (dihydroquercetin, p-thyrozol, dibornol, and prostagenin) on prostate morphology. All examined agents decreased the degree of hyperplasia in acinar epithelium; the greatest efficacy was demonstrated by prostagenin. Moreover, dihydroquercetin and p-thyrozol increased the cross-section area of acinar lumina and prostate volume, which is inadmissible in this pathology. These results suggest that the use of phenolic antioxidants in the therapy of benign prostatic hyperplasia should be strictly controlled.
Sobre autores
T. Borovskaya
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Autor responsável pela correspondência
Email: repropharm@yandex.ru
Rússia, Tomsk
S. Kamalova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Rússia, Tomsk
V. Grigor’eva
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Rússia, Tomsk
M. Poluektova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Rússia, Tomsk
A. Vychuzhanina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Rússia, Tomsk
A. Kuchin
Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
Email: repropharm@yandex.ru
Rússia, Syktyvkar
I. Chukicheva
Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
Email: repropharm@yandex.ru
Rússia, Syktyvkar
E. Buravlev
Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
Email: repropharm@yandex.ru
Rússia, Syktyvkar
T. Fomina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Rússia, Tomsk
M. Plotnikov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Rússia, Tomsk
V. Goldberg
Research Institute of Oncology, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Rússia, Tomsk
A. Dygai
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
Rússia, Tomsk
![](/img/style/loading.gif)